GENE ONLINE|News &
Opinion
Blog

2022-08-30| COVID-19

Moderna Wins the First Regulatory Approval for an Omicron Bivalent Vaccine

by Max Heirich
Share To

On August 30, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia granted provisional approval for the company’s bivalent Omicron vaccine. This approval marks the first granted worldwide by a regulatory body. 

Related Article: Moderna’s Lawsuit Against Pfizer/BioNTech: What Does This Mean for Their Vaccine’s future?

The Wave of Pending Bivalent Omicron Vaccines

Bivalent vaccines grant protection against two different strains of a disease. With the onset of the Omicron strain of COVID-19 in November of 2021, the previously approved vaccines did not provide as effective defense as they did against the original COVID-19 strain. As a result, pharmaceutical companies began developing updated vaccines to protect against these new strains. 

Moderna developed mRNA-1273.214, an improvement on their original Spikevax vaccine, now containing mRNA code for protection against Omicron subvariants BA.1. Omicron BA.1 is the original Omicron strain, having since further mutated to four other distinct subvarants. 

This August saw various submissions to regulatory bodies for the approval of the bivalent Omicron vaccine. Not only did Moderna submit mRNA-1273.214 to the United States Food and Drug Administration (FDA), but Pfizer also submitted their own vaccine. The vaccines co-produced by Pfizer and BioNTech provide defense against Omicron subvariants BA.4/BA.5. These two strains are further mutations of the original Omicron strain, BA.1. Since their emergence in May of this year, together, they caused over 80% of new COVID-19 cases. 

However, today marks the first approval granted by a regulatory agency for any bivalent omicron vaccine.

The First Approved Omicron Bivalent Vaccine

Australia’s TGA granted provisional approval for Moderna’s mRNA-1273.214 protecting against Omicron BA.1. The basis of the approval was the results found in a phase ⅔ clinical trial. The trial demonstrated that mRNA-1273.214 met all of its primary endpoints. Namely, the bivalent vaccine showed an eight-fold improvement in killing Omicron than Moderna’s original vaccine, mRNA-1273, had. In addition, the bivalent Omicron vaccine’s safety profile matched that of mRNA-1273.

This approval comes just days after Moderna filled lawsuits against Pfizer and BioNTech for allegedly copying their mRNA technology

On the approval, Arpa Garay, Chief Commercial Officer at Moderna, said, “We are delighted to receive provisional approval from the TGA for our next-generation bivalent vaccine, mRNA-1273.214. Australia becomes one of the first countries in the world to approve an Omicron-containing vaccine, highlighting its continued stewardship in the fight against COVID-19. This is a vital step in helping to keep the Australian people safe from the ongoing threat that COVID-19 represents to global public health.”

The TGA’s approval marks a positive milestone for the approval of Moderna’s Bivalent Omicron Vaccine. In the coming weeks, other regulatory bodies will likely follow suit and grant approval for the new vaccine.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Controversy Surrounds Jay Bhattacharya’s Nomination as NIH Director
2025-03-05
Study Reveals Distinct Immune Signatures in Myocarditis Linked to COVID-19 and Vaccines
2025-02-25
LATEST
Finnish Study Finds Brain Biomarkers for Alzheimer’s Detectable in Middle Age
2025-07-14
Blood Test Developed at Medical University of Vienna Predicts Multiple Sclerosis Risk Years Before Symptoms
2025-07-14
University of Tokyo Researchers Develop In Vivo System to Study Senescent Cells in Aging
2025-07-14
Relmada Therapeutics Ends Development of Depression Drug Esmethadone and Terminates Licensing Agreement
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton in Narcolepsy Treatment
2025-07-14
Takeda Pharmaceuticals Reports Positive Phase 3 Trial Results for Narcolepsy Drug Targeting Daytime Sleepiness and Cataplexy
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton Targeting Orexin Proteins in Narcolepsy Treatment
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top